Further elucidation of the mechanisms underlying stabilization of tau in vivo may reveal additional therapeutic targets that could effectively lower tau levels, thereby counteracting complex tau toxicity in AD and other tauopathies. This evidence concerns the gene MAPT and Alzheimer disease.